Clinical Trial: Page 5

Interpace Biosciences announces data for test to assess indeterminate thyroid nodules

By LabPulse.com staff writers

The data support both versions of its test platform and a blinded analysis of pairwise miRNA expression profiling demonstrated greater accuracy than its original testing platform, the firm said.

October 21, 2022

Biofidelity developing assay for single-molecule detection of multiple gene fusions

By LabPulse.com staff writers

The firm said its assay analyzes DNA and RNA concurrently from a single patient sample and can return results within two days.

October 18, 2022

Multicenter study highlights deficiencies in invasive lobular carcinoma assessment

By Maryam Payne

The researchers emphasized that the study results, and the difficulties inherent in detecting ILC on mammograms, demonstrate the need for molecular tests specifically designed for ILC.

October 17, 2022

GTC reports on validation of targeted transcriptome algorithms for diagnostic use

By LabPulse.com staff writers

GTC’s RNAnalysis algorithm is used to distinguish between 45 different diagnostic classes, providing probability scores. The algorithm is complemented by a second one called TraceWork.

October 13, 2022

Thermo Fisher announces decentralized clinical trials network

By LabPulse.com staff writers

Decentralized clinical trials afford greater access to these trials for patients who previously may have been unable to participate because of a variety of personal factors.

October 5, 2022

Daxor highlights study on test in heart failure management

By LabPulse.com staff writers

Daxor highlighted results of a study from Duke Heart validating the utility of the firm's diagnostic blood test in optimizing the therapeutic management of heart failure patients.

October 3, 2022

Enzo launches RNA gene expression platform for HPV

By LabPulse.com staff writers

The platform's products combine sequence-specific probes with Enzo's LoopRNA in situ hybridization (ISH) technology, enabling the products to detect target genes in tissue or cell samples while preserving the morphology, Enzo said. This study of single cells within their native tissue environment, called spatial biology, helps scientists characterize and understand disease, Enzo added.

September 25, 2022

Leuko nabs $5M for validation of WBC monitoring technology

By LabPulse.com staff writers

HTH VC, Good Growth Capital, IAG Capital Partners, Nina Capital, and angel investors provided the funding, Leuko said. The funding will allow the company to accelerate clinical trials with the aim of obtaining regulatory approval in collaboration with leading cancer centers, including the MD Anderson Cancer Center and Boston Medical Center in the U.S., and Dexeus and Hospital 12 de Octubre in Spain.

September 22, 2022

Reading blood-oxygen saturation levels on a smartphone

By Jared Berberabe

In the study, University of Washington and University of California San Diego researchers demonstrated that the use of a smartphone camera and flash could enable detection of blood oxygen saturation levels comparable to those measured in a clinic using a pulse oximeter clipped to a finger.

September 20, 2022

Qiagen, Neuron23 to develop CDx for Parkinson’s

By LabPulse.com staff writers

Under the agreement, Qiagen will develop and validate a clinical trial assay that will detect a combination of biomarkers discovered by Neuron23 that together predict the responsiveness of Parkinson's disease to a LRRK2 inhibitor.

September 13, 2022

Nordic touts PRO-C6 biomarker for heart failure clinical trials

By LabPulse.com staff writers

In collaboration with Bristol Myers Squibb and the University of Pennsylvania, researchers combined analyses of six independent cohorts of HFpEF patients from around the globe, which are being evaluated with the PRO-C6 biomarker.

September 13, 2022

Natera presents colorectal, breast cancer data at ESMO 2022

By LabPulse.com staff writers

One abstract, related to the Bellini trial, examined the potential clinical utility of circulating tumor DNA (ctDNA) in assessing the response to neoadjuvant immunotherapy in patients with early-stage (I-II) triple-negative breast cancer (TNBC).

September 12, 2022

Previous Page

Page 5 of 18

Next Page